DiscoverThe Biotech Startups Podcast
The Biotech Startups Podcast
Claim Ownership

The Biotech Startups Podcast

Author: Excedr

Subscribed: 7Played: 136
Share
Copyrights © 2024 All Rights Reserved by Excedr

Description

Welcome to The Biotech Startups Podcast by Excedr. Join us as we speak with first-time founders, experienced scientists, long-time company operators, serial entrepreneurs, and biotech investors about the challenges and triumphs of running a biotech startup. Gain actionable insight into navigating the ever-changing life sciences industry in each episode as we explore the business of science, from pre-seed to IPO. With your host, Jon Chee.
46 Episodes
Reverse
🧬 Grant Aarons - FabricNano - Part 1 | How NYC Shaped a Love of Engineering | Benefitting from Great Diversity at Cooper Union | Experiences & Opportunities at the Federal Reserve Bank of New York | Impact of the Economy on Deep Tech

🧬 Grant Aarons - FabricNano - Part 1 | How NYC Shaped a Love of Engineering | Benefitting from Great Diversity at Cooper Union | Experiences & Opportunities at the Federal Reserve Bank of New York | Impact of the Economy on Deep Tech

2024-05-1538:15

Part 1 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform. With clients ranging from startups to multinationals like Sumitomo Chemical Company, FabricNano provides highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals.
🧬 Bryan Dechairo - Sherlock Biosciences - Part 3 | Assurex’s Journey From Garage to GeneSight | Keeping a Team Together Through the M&A Process | Building a Diagnostics Company During Covid | What Sherlock & Netflix Have in Common

🧬 Bryan Dechairo - Sherlock Biosciences - Part 3 | Assurex’s Journey From Garage to GeneSight | Keeping a Team Together Through the M&A Process | Building a Diagnostics Company During Covid | What Sherlock & Netflix Have in Common

2024-05-0850:28

Part 3 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.
🧬 Bryan Dechairo - Sherlock Biosciences - Part 2 | Transitioning From a Small Startup to Pfizer | Big Data's Role in Modern Genetics | Building & Leading Dynamic Teams | The Evolution of Personalized Medicine

🧬 Bryan Dechairo - Sherlock Biosciences - Part 2 | Transitioning From a Small Startup to Pfizer | Big Data's Role in Modern Genetics | Building & Leading Dynamic Teams | The Evolution of Personalized Medicine

2024-05-0134:14

Part 2 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.
🧬 Bryan Dechairo - Sherlock Biosciences - Part 1 | A Love of Science Blossoming from a 10-Acre Hobby Farm | Experiencing Great Diversity at UC Berkeley | Growth & Enjoyment of Startups | Unexpected Travels to Pursue a Dream Overseas

🧬 Bryan Dechairo - Sherlock Biosciences - Part 1 | A Love of Science Blossoming from a 10-Acre Hobby Farm | Experiencing Great Diversity at UC Berkeley | Growth & Enjoyment of Startups | Unexpected Travels to Pursue a Dream Overseas

2024-04-2433:07

Part 1 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health. The Sherlock team and founders include engineering biology pioneers with world-leading expertise in CRISPR and synthetic biology, diagnostic industry veterans, and disease area authorities.
🧬 Terry Lo - Vizgen - Part 3 | Transitioning to Vizgen From Akoya | What is Spatial Genomics | The Importance of Genetic Mapping | How to Grow Your Company During Turbulent Times

🧬 Terry Lo - Vizgen - Part 3 | Transitioning to Vizgen From Akoya | What is Spatial Genomics | The Importance of Genetic Mapping | How to Grow Your Company During Turbulent Times

2024-04-1730:05

Part 3 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.
🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations

🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations

2024-04-1030:18

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.
🧬 Terry Lo - Vizgen - Part 1 | Leveraging Passion for Science to Succeed in Finance | Sales Excellence as an Introvert Through Competition | Financial Modeling & Creating Proper Deal Structure | How Not To Be A Jack of All Trades

🧬 Terry Lo - Vizgen - Part 1 | Leveraging Passion for Science to Succeed in Finance | Sales Excellence as an Introvert Through Competition | Financial Modeling & Creating Proper Deal Structure | How Not To Be A Jack of All Trades

2024-04-0338:15

Part 1 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Vizgen’s technology will aid the acceleration of biological research and discovery to advance human health
🧬 Mike Stadnisky - Thielsen Capital - Part 3 | Don’t Fake it ‘Til you Make It | Cleaning Your Corporate “Underwear” | Thielsen’s Investment Philosophy | The Critical Importance of Alignment

🧬 Mike Stadnisky - Thielsen Capital - Part 3 | Don’t Fake it ‘Til you Make It | Cleaning Your Corporate “Underwear” | Thielsen’s Investment Philosophy | The Critical Importance of Alignment

2024-03-2757:58

Part 3 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science.
🧬 Mike Stadnisky - Thielsen Capital - Part 2 | Transitioning from Academia to Business | Breaking Into Business Development | Finding Decision Makers & Champions | Navigating Partnerships & Strategy

🧬 Mike Stadnisky - Thielsen Capital - Part 2 | Transitioning from Academia to Business | Breaking Into Business Development | Finding Decision Makers & Champions | Navigating Partnerships & Strategy

2024-03-2034:46

Part 2 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.
🧬 Mike Stadnisky - Thielsen Capital - Part 1 | Familial Exposure to Business & Science at a Young Age | The Importance of “Care Before You Share” | Actively Managing Your Time | A PhD is a 10,000 Hour Degree

🧬 Mike Stadnisky - Thielsen Capital - Part 1 | Familial Exposure to Business & Science at a Young Age | The Importance of “Care Before You Share” | Actively Managing Your Time | A PhD is a 10,000 Hour Degree

2024-03-1350:51

Part 1 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.
🧬 Martin Brenner - iBio - Part 3 | Transitioning from Big Pharma to Biotech Startups | Lessons in Flexibility, Resilience, & Adaptability | Challenging Long-Held Beliefs in Drug Discovery | The Evolution & Future of iBio

🧬 Martin Brenner - iBio - Part 3 | Transitioning from Big Pharma to Biotech Startups | Lessons in Flexibility, Resilience, & Adaptability | Challenging Long-Held Beliefs in Drug Discovery | The Evolution & Future of iBio

2024-03-0601:21:04

Part 3 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
🧬 Martin Brenner - iBio - Part 2 | Autonomy at Eli Lilly vs. Structure at Pfizer | Transitioning from AstraZeneca to Merck | Joys & Challenges When Relocating for Work | A Biotech Vision Leading to an Exit From Big Pharma

🧬 Martin Brenner - iBio - Part 2 | Autonomy at Eli Lilly vs. Structure at Pfizer | Transitioning from AstraZeneca to Merck | Joys & Challenges When Relocating for Work | A Biotech Vision Leading to an Exit From Big Pharma

2024-02-2836:53

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
🧬 Martin Brenner - iBio - Part 1 | How Childhood Influences Shape Career Paths | Unexpected Crossovers Between Engineering & Veterinary Clinics | Eli Lilly Nurturing His Professional Development | Communication Can Make or Break Leadership

🧬 Martin Brenner - iBio - Part 1 | How Childhood Influences Shape Career Paths | Unexpected Crossovers Between Engineering & Veterinary Clinics | Eli Lilly Nurturing His Professional Development | Communication Can Make or Break Leadership

2024-02-2133:31

Part 1 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.
🧬 Jeff Kim - Slingshot Biosciences - Part 3 | Bucking the Status Quo | Raising Capital During Peak COVID | How To Find & Retain Great Talent | Building Partnerships with Distributors

🧬 Jeff Kim - Slingshot Biosciences - Part 3 | Bucking the Status Quo | Raising Capital During Peak COVID | How To Find & Retain Great Talent | Building Partnerships with Distributors

2024-02-1428:52

Part 3 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.
🧬 Jeff Kim - Slingshot Biosciences - Part 2 | Working Toward One Goal In Industry | How Great Loss Prompted Professional Growth | Transitioning From a Basement Lab to a Thriving Company | A 6-Month Startup Idea Exceeding 12 Years of Operation

🧬 Jeff Kim - Slingshot Biosciences - Part 2 | Working Toward One Goal In Industry | How Great Loss Prompted Professional Growth | Transitioning From a Basement Lab to a Thriving Company | A 6-Month Startup Idea Exceeding 12 Years of Operation

2024-02-0731:53

Part 2 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.
🧬 Jeff Kim - Slingshot Biosciences - Part 1 | Parental Freedom, Curiosity, & Self-Teaching | Music Accentuating a Passion for Science | The Benefits of Graduate Responsibilities as an Undergrad | Finding Fit & Balancing Research & the Arts

🧬 Jeff Kim - Slingshot Biosciences - Part 1 | Parental Freedom, Curiosity, & Self-Teaching | Music Accentuating a Passion for Science | The Benefits of Graduate Responsibilities as an Undergrad | Finding Fit & Balancing Research & the Arts

2024-01-3128:32

My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.
🧬 Stephanie Sirota - RTW Investments - Part 3 | The Emergence of Crossover Rounds | Building & Explaining Your Investment Thesis | Creating a .600 Batting Average Investment Fund | Transparency Between Investor & Founder | How to Get LPs to Say “Yes”

🧬 Stephanie Sirota - RTW Investments - Part 3 | The Emergence of Crossover Rounds | Building & Explaining Your Investment Thesis | Creating a .600 Batting Average Investment Fund | Transparency Between Investor & Founder | How to Get LPs to Say “Yes”

2024-01-2431:40

Part 3 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.
🧬 Stephanie Sirota - RTW Investments - Part 2 | Understanding Investment Banking’s Role in the Biosciences | Finding the Benefits of Your Uniqueness | Unexpected Pivots & Finding Passion in Your Work | Advice on Dealing with Bear Markets

🧬 Stephanie Sirota - RTW Investments - Part 2 | Understanding Investment Banking’s Role in the Biosciences | Finding the Benefits of Your Uniqueness | Unexpected Pivots & Finding Passion in Your Work | Advice on Dealing with Bear Markets

2024-01-1733:13

Part 2 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.
🧬 Stephanie Sirota - RTW Investments - Part 1 | Early Influences on Leadership Style | Competitive Tennis Fosters Professional Drive | The Inverse Importance of Coaching | The Ending of a Dream to Open New Doors | Organically Choosing Your Track

🧬 Stephanie Sirota - RTW Investments - Part 1 | Early Influences on Leadership Style | Competitive Tennis Fosters Professional Drive | The Inverse Importance of Coaching | The Ending of a Dream to Open New Doors | Organically Choosing Your Track

2024-01-1024:34

Part 1 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.
🧬 Kittu Kolluri - Neotribe Ventures - Part 3 | Influence vs Control as a VC | Being a Leader in Venture vs a Leader in a Company | Starting Neotribe as a Passionate Rage Against the Status Quo | Sunk Cost vs Opportunity Cost | Optimizing Customer Acquisit

🧬 Kittu Kolluri - Neotribe Ventures - Part 3 | Influence vs Control as a VC | Being a Leader in Venture vs a Leader in a Company | Starting Neotribe as a Passionate Rage Against the Status Quo | Sunk Cost vs Opportunity Cost | Optimizing Customer Acquisit

2024-01-0336:51

Part 3 of 3. My guest for this week’s episode is Kittu Kolluri, Founder and Managing Director of Neotribe Ventures, an early- and growth-stage venture capital firm investing in companies that solve hard technical problems and disrupt non-traditional industry sectors.
loading
Comments 
loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States